Key result
Various cancer treatments can cause cardiovascular toxicities that often require temporary or permanent cessation of the anti-neoplastic drug and optimization of cardiovascular medical management.
Cancer therapies are associated with significant cardiovascular toxicities that require specialized management, including potential adjustment of oncologic regimens.
Requires cardio-oncology input during cancer therapy; extends toxicity literature but leaves optimal protocols open.
Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.
No takes yet. Share an insight, caveat, or question.
Ruddy et al. (2020) conducted a review in Cardiovascular toxicities from cancer therapy. Cancer therapies (radiation, anthracyclines, targeted therapies, etc.) was evaluated. Various cancer treatments can cause cardiovascular toxicities that often require temporary or permanent cessation of the anti-neoplastic drug and optimization of cardiovascular medical management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: